Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)Samuel Q. Li, Javed Khan, Jack F. Shern et al.|PLoS ONE|2013Cited by 100